Global Aminoglycosides Antibiotics Market Insights and Forecast to 2028

Aminoglycosides are a class of antibiotics used mainly in the treatment of aerobic gram-negative bacilli infections, although they are also effective against other bacteria including Staphylococci and Mycobacterium tuberculosis. They are often used in combination with other antibiotics.
Market Analysis and Insights: Global Aminoglycosides Antibiotics Market
Due to the COVID-19 pandemic, the global Aminoglycosides Antibiotics market size is estimated to be worth US$ 1079.8 million in 2022 and is forecast to a readjusted size of US$ 1244.9 million by 2028 with a CAGR of 2.4% during the review period. Fully considering the economic change by this health crisis, Neomycin accounting for % of the Aminoglycosides Antibiotics global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Hospital segment is altered to an % CAGR throughout this forecast period.
The classification of Aminoglycosides Antibiotics includes Neomycin, Tobramycin, Gentamicin, Amikacin, Etimicin and Others. In addition, the proportion of Neomycin in 2019 is about 26%, and Etimicin mainly sales in China.
Aminoglycosides Antibiotics is widely used for Hospital, Clinic, Post Care Facility, Government & Military and Others. The most proportion of Aminoglycosides Antibiotics is for clinic, and the proportion in 2019 is about 35%.
Europe is the largest consumption place, with a consumption market share nearly 26% in 2019. Following Europe, China is the second largest consumption place with the consumption market share of about 16%.
Jemicare, Teva, Novartis Pharmaceuticals, Fangyuan-pharma, Aike Pharmaceutical, Cipla, etc. are the leaders of the industry.
Global Aminoglycosides Antibiotics Scope and Segment
Aminoglycosides Antibiotics market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Aminoglycosides Antibiotics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Neomycin
Tobramycin
Gentamicin
Amikacin
Etimicin
Others
Segment by Application
Hospital
Clinic
Post Care Facility
Government & Military
Others
By Company
Jemicare
Teva
Novartis
Fangyuan-pharma
Aike Pharmaceutical
Cipla
Pfizer
Fresenius Kabi
Sun Pharma
Hikma
Lannett Company
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE